Sustained Anti-VEGF Delivery via Hydrogel Implant Achieves Non-Inferior Visual and Anatomical Outcomes in Neovascular AMD: A 24-Month Randomized Controlled Trial
Sriwijaya Journal of Ophthalmology · 19.06.2026 · 8 (2) · 486-493
DOI: 10.37275/sjo.v8i2.138 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Sriwijaya Journal of Ophthalmology, online erschienen am 19.06.2026. Verfasst von Habiburrahman Said und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Neovascular age-related macular degeneration (nAMD) requires frequent anti-VEGF intravitreal injections, creating substantial treatment burden. This study compared the 24-month efficacy and safety of a sustained-release anti-VEGF hydrogel implant versus monthly ranibizumab in treatment-naive nAMD eyes.
Methods
This prospective randomized controlled trial enrolled 126 eyes (96 patients; 30 bilateral) with treatment-naive nAMD at a private hospital in Palembang, Indonesia (January 2022–December 2024). Eyes were randomized 1:1 to a biodegradable anti-VEGF hydrogel implant (n=64) or monthly ranibizumab 0.5 mg (n=62). The primary outcome was non-inferiority of the mean best-corrected visual acuity (BCVA) change (LogMAR) at 24 months (margin: 0.10 LogMAR). Analyses used linear mixed-effects models with generalized estimating equations to account for inter-eye correlation.
Results
Mean BCVA improved by −0.24±0.18 LogMAR (≈12 letters) in the hydrogel group and −0.22±0.20 LogMAR (≈11 letters) in the ranibizumab group (difference: −0.02; 95% CI: −0.09 to 0.05; p=0.578; non-inferiority confirmed). The hydrogel group required 77.8% fewer injections (4.8±1.2 vs 21.6±3.4; p
Zitieren
APA
Said, H., Putri, O. A., & Purnama, L. (2026). Sustained Anti-VEGF Delivery via Hydrogel Implant Achieves Non-Inferior Visual and Anatomical Outcomes in Neovascular AMD: A 24-Month Randomized Controlled Trial. Sriwijaya Journal of Ophthalmology, 8(2), 486-493. https://doi.org/10.37275/sjo.v8i2.138
Vancouver
Said H, Putri OA, Purnama L. Sustained Anti-VEGF Delivery via Hydrogel Implant Achieves Non-Inferior Visual and Anatomical Outcomes in Neovascular AMD: A 24-Month Randomized Controlled Trial. Sriwijaya Journal of Ophthalmology. 2026;8(2):486-493. doi:10.37275/sjo.v8i2.138
BibTeX
@article{Said2026,
author = {Said, Habiburrahman and Putri, Oliva Azalia and Purnama, Linda},
title = {Sustained Anti-VEGF Delivery via Hydrogel Implant Achieves Non-Inferior Visual and Anatomical Outcomes in Neovascular AMD: A 24-Month Randomized Controlled Trial},
journal = {Sriwijaya Journal of Ophthalmology},
year = {2026},
volume = {8},
number = {2},
pages = {486--493},
doi = {10.37275/sjo.v8i2.138}
}
EUVIMED